Why Publish with Open Forum Infectious Diseases?
Open Forum Infectious Diseases (OFID) publishes clinical, translational and basic research in a fully open access, online journal. It focuses on the intersection of biomedical science and clinical practice, with an emphasis on knowledge that could improve patient care globally. OFID is an official publication of the Infectious Diseases Society of America. With an Impact Factor of 3.8, the journal is ranked 34 out of 132 journals in the field of infectious diseases.
Fast Publication Speed
Manuscripts are first published within 24-72 hours of acceptance; corrected proofs are published within 3-5 weeks.
Ease of Submission
The journal offers format free submissions, as well as an efficient transfer process to Clinical Infectious Diseases or The Journal of Infectious Diseases. OFID particularly welcomes manuscripts redirected with earlier reviews from IDSA’s other journals. The average time to first decision with peer review is 34.8 days.
Distinguished Editorial Board
Members of the OFID Editorial Board are recruited and appointed based on their expertise in the field. The board ensures the journal publishes high-quality content, operates ethically, and provides a welcoming publishing outlet for authors from all backgrounds and at all career stages.
Meet OFID's Editor-in-Chief
Roger J. Bedimo, MD, is the Chief of Infectious Diseases Section at the VA North Texas Health Care System and Professor of Medicine at the University of Texas Southwestern Medical Center in Dallas. He’s also the leader of the Trinity Clinical Research Site of the AIDS Clinical Trials Group. Dr. Bedimo has been actively involved in HIV clinical care and research since 2003. He completed his medical education at the University of Yaoundé in Cameroon. He then completed internal medicine residency training at Wright State University in Dayton, Ohio, and infectious diseases fellowship training at the University of Alabama at Birmingham. His main research is analysis of determinants and mechanisms of chronic complications of HIV disease. He is member of the DHHS guidelines panels for adult antiretroviral therapy and COVID-19 disease. Discoverability
Authors publishing in the journal benefit from a wide array of services to help support discoverability, including OUP’s platform capabilities, self-promotion tools, and IDSA’s social media and other communications vehicles, including OFID’s X presence @OFIDJournal. With an average of more than 160,000 visits with content engagement per month, your article will receive significant exposure.
Open Access
If you prefer to make your work available under an open access license, or your funder requires open access publication, OFID offers these options.
